SRTD Biotech
SRTD Biotech is pioneering the next level of mRNA technology with its innovative seRNA platform, aiming to develop highly specific, fast, universal, and revolutionary RNA-based therapies for diseases such as cancer, viral infections, and autoimmune disorders. Their mission is to open a new chapter in disease treatment by delivering selectively expressed RNAs (seRNAs) to patients, utilizing proprietary technology including fLNPs and fusogenic liposomes for targeted delivery. The company is committed to advancing treatments for high medical need indications like liver cancer, glioblastoma, lung cancer, and autoimmune diseases, with a focus on efficacy, specificity, and safety.
Industries
Nr. of Employees
small (1-50)
SRTD Biotech
Huthmacherstrasse 20, 52428 Jülich, Germany
Patents
System and method for cell type-specific translation of RNA molecules in eukaryotes
US-12180470-B2
View Details
System and method for cell type-specific translation of RNA molecules in eukaryotes
US-12180470-B2
View DetailsProducts
seRNA 001 — liver cancer (HCC) candidate
Platform-derived selectively expressed RNA candidate targeting hepatocellular carcinoma; development pathway includes in vitro and in vivo POC and planned IND-enabling studies.
seRNA 002 — lung cancer candidate
Platform RNA candidate targeting lung cancer, currently at early (seed) development milestones.
seRNA 003 — glioblastoma candidate
Locally applied platform RNA candidate developed for glioblastoma with in vitro and in vivo proof-of-concept data; currently open for research or development partnerships.
seRNA 004 — viral disease candidate (platform adaptation)
Platform-adapted RNA constructs proposed for antiviral indications; development status undisclosed.
seRNA 005 — autoimmune disease candidate (platform adaptation)
Platform-adapted candidate proposed for autoimmune indications that leverages immune-cell–specific transcript markers for targeted activation; development status undisclosed.
seRNA 001 — liver cancer (HCC) candidate
Platform-derived selectively expressed RNA candidate targeting hepatocellular carcinoma; development pathway includes in vitro and in vivo POC and planned IND-enabling studies.
seRNA 002 — lung cancer candidate
Platform RNA candidate targeting lung cancer, currently at early (seed) development milestones.
seRNA 003 — glioblastoma candidate
Locally applied platform RNA candidate developed for glioblastoma with in vitro and in vivo proof-of-concept data; currently open for research or development partnerships.
seRNA 004 — viral disease candidate (platform adaptation)
Platform-adapted RNA constructs proposed for antiviral indications; development status undisclosed.
seRNA 005 — autoimmune disease candidate (platform adaptation)
Platform-adapted candidate proposed for autoimmune indications that leverages immune-cell–specific transcript markers for targeted activation; development status undisclosed.
Services
In-licensing and further development of fusogenic lipid-based delivery systems for nucleic acid therapies, including formulation and organ pre-targeting optimization.
Execution and coordination of preclinical in vitro and in vivo studies (biodistribution, efficacy, tolerability) including partnerships with CROs for extended animal studies.
In-licensing and further development of fusogenic lipid-based delivery systems for nucleic acid therapies, including formulation and organ pre-targeting optimization.
Execution and coordination of preclinical in vitro and in vivo studies (biodistribution, efficacy, tolerability) including partnerships with CROs for extended animal studies.
Expertise Areas
- RNA therapeutics platform development
- Targeted RNA delivery using lipid-based nanoparticles
- Preclinical in vivo efficacy and biodistribution studies
- Modular RNA construct engineering combining RNAi and mRNA
Key Technologies
- Selective activation RNA pro-drug constructs
- RNA interference (RNAi)-based targeting
- mRNA-mediated effector expression
- Fusogenic lipid nanoparticles (LNPs) for systemic delivery
News & Updates
The seRNA principle and its in vitro and in vivo proof of concept studies are published, demonstrating the platform's potential against cancer and viral diseases.
fLNP technology demonstrated its transfer efficiency and organ-specific pre-targeting in biodistribution studies, confirming its potential for seRNA delivery.
The company closed its first financing round, led by HTGF, to accelerate the development of its proprietary seRNA technology, aiming to bring drug candidates into clinical development.
seRNA treatment stopped tumor growth in a breast cancer mouse model with no toxic side effects, demonstrating high efficacy and specificity.
The seRNA principle and its in vitro and in vivo proof of concept studies are published, demonstrating the platform's potential against cancer and viral diseases.
fLNP technology demonstrated its transfer efficiency and organ-specific pre-targeting in biodistribution studies, confirming its potential for seRNA delivery.
The company closed its first financing round, led by HTGF, to accelerate the development of its proprietary seRNA technology, aiming to bring drug candidates into clinical development.
seRNA treatment stopped tumor growth in a breast cancer mouse model with no toxic side effects, demonstrating high efficacy and specificity.